Market Cap 229.75M
Revenue (ttm) 134.48M
Net Income (ttm) -38.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28.96%
Debt to Equity Ratio 0.00
Volume 427,500
Avg Vol 734,264
Day's Range N/A - N/A
Shares Out 41.40M
Stochastic %K 15%
Beta 1.24
Analysts Hold
Price Target $8.79

Company Profile

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 521 7830
Website: rxsight.com
Address:
100 Columbia, Aliso Viejo, United States
BryGuy29
BryGuy29 May. 7 at 2:01 PM
$RXST yikes. Great tech, but honestly, this company should be acquired by a bigger company to open the tech to more offices.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 8:10 PM
$RXST Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.38 down -90.00% YoY • Reported revenue of $30.89M down -18.48% YoY • RxSight expects to incur net operating losses and negative cash flows for the foreseeable future, despite anticipating revenue growth from expanded sales and marketing efforts, with current cash sufficient for at least 12 months.
0 · Reply
SuperGreenToday
SuperGreenToday May. 1 at 6:39 PM
0 · Reply
OPmoney
OPmoney Apr. 23 at 6:02 PM
$RXST PSA update after 22 days Post-Op: 4/21 was 1st UV tweek to LALs - looking at seeing 20/15 in both eyes. Still wearing UV blocker dark sunglasses, iVIZIA Sterile Lubricant Eye Drops for Dry Eyes every hour or two, using +2.75 readers for close work and +1.25 for desk/computer screens. So far, so good, clearer and brighter - future so bright ...
1 · Reply
focafoca99
focafoca99 Apr. 8 at 10:21 PM
$RXST highlighted the milestone of 300,000 Light Adjustable Lens implants and a heavy scientific presence at ASCRS 2026.
0 · Reply
OPmoney
OPmoney Apr. 6 at 7:21 PM
$RXST PSA #1 from 2025: As far as posting up insight on another patient's own LAL experience Nov. 2023 in one eye. There is some improvement. Can see because cataract was removed, however doctor's recent reco, after a year of own blood Serum-eyedrops for severe dry eye is now try Oxervate $100K eye drops. As of 10-days ago cornea looks like "sand paper." Same thing was said after lock-in over a year ago. NO FUN, plus this patient also suffers from Trigeminal neuralgia - no pain- only numbness on same side of face as LAL since. While there is visual improvement since the cataract was removed, the road post "lock-in" has been complicated by chronic ocular surface issues: The "Sandpaper" Effect: A recent exam revealed the cornea still looks like "sandpaper." This is the same condition reported after the initial lock-in over a year ago. The battle with corneal health continues. It’s a reminder that even with the best lens technology, the "window" (the cornea) has to be clear for it to work.
1 · Reply
OPmoney
OPmoney Apr. 6 at 7:09 PM
$RXST PSA: After undergoing a vitrectomy in both eyes this past September, then earning early onset cataracts - I just spent 10K and am now the proud owner of RxSight Light Adjustable Lenses (LALs) in each eye. Here is the current status: Distance Vision: Five days post-op and things are looking pretty clear in both. AMAZING how clear and bright everything is. The Rx does not match. There is a glare line in dark, looking at lightbulb from 11 to 5 in left and 10 to 4 in right. Near Vision: Currently using +2.75 readers for typing and close work. Maintenance: On a regimen of eye drops 3x daily. UV Dark Glasses mandatory outdoors, not so much indoors. Next Steps: Follow-up appointment scheduled in 10 days. So far, so good! It’s quite an investment, but the progress is encouraging. Added one new "floater" in left eye and two in the right. 1st lock-in is weeks away. Feel free to DM with any questions or concerns.
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:29 PM
$RXST to appear at the Needham Virtual Healthcare Conference on April 16.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 3:52 PM
$RXST Share Price: $6.33 Contract Selected: Sep 18, 2026 $5 Calls Buy Zone: $2.52 – $3.12 Target Zone: $4.34 – $5.30 Potential Upside: 62% ROI Time to Expiration: 174 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
KOWALSK1
KOWALSK1 Mar. 23 at 10:46 AM
$RXST Rxsight inc. ✅️ BUY ZONE 6.41 to 6.35 ✋️ RISK BELOW 6.18 💲PT. 6.75 6.80 7.20 7.64 8.10 + Follow for more
0 · Reply
Latest News on RXST
RxSight price target lowered to $11 from $13 at Needham

2026-05-07T13:37:20.000Z - 7 days ago

RxSight price target lowered to $11 from $13 at Needham


RxSight reports Q1 adjusted EPS (19c), consensus (15c)

2026-05-07T00:52:25.000Z - 8 days ago

RxSight reports Q1 adjusted EPS (19c), consensus (15c)


RxSight Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 8 days ago

RxSight Earnings Call Transcript: Q1 2026


RxSight price target lowered to $9 from $10 at Stifel

2026-03-09T11:16:16.000Z - 2 months ago

RxSight price target lowered to $9 from $10 at Stifel


RxSight price target lowered to $10 from $11 at Piper Sandler

2026-02-26T13:26:59.000Z - 2 months ago

RxSight price target lowered to $10 from $11 at Piper Sandler


RxSight price target raised to $9 from $8 at UBS

2026-02-26T13:15:33.000Z - 2 months ago

RxSight price target raised to $9 from $8 at UBS


RxSight reports Q4 EPS (3c), consensus (20c)

2026-02-25T21:49:05.000Z - 2 months ago

RxSight reports Q4 EPS (3c), consensus (20c)


RxSight sees FY26 revenue $120M-$135M, consensus $135.34M

2026-02-25T21:47:02.000Z - 2 months ago

RxSight sees FY26 revenue $120M-$135M, consensus $135.34M


RxSight Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 2 months ago

RxSight Earnings Call Transcript: Q4 2025


RxSight initiated with a Market Perform at William Blair

2026-01-30T11:45:23.000Z - 3 months ago

RxSight initiated with a Market Perform at William Blair


RxSight price target raised to $11 from $10 at Piper Sandler

2026-01-20T11:52:30.000Z - 4 months ago

RxSight price target raised to $11 from $10 at Piper Sandler


RxSight appoints Wilterding as CFO

2026-01-11T19:20:25.000Z - 4 months ago

RxSight appoints Wilterding as CFO


RxSight reports preliminary Q4 revenue $32.6M, consensus $27.5M

2026-01-11T19:20:19.000Z - 4 months ago

RxSight reports preliminary Q4 revenue $32.6M, consensus $27.5M


RxSight raises FY25 revenue guidance to $134.5M vs $125M-$130M

2026-01-11T19:20:10.000Z - 4 months ago

RxSight raises FY25 revenue guidance to $134.5M vs $125M-$130M


RxSight announces CFO transition

2025-12-22T22:25:21.000Z - 5 months ago

RxSight announces CFO transition


RxSight, Inc. Announces Chief Financial Officer Transition

Dec 22, 2025, 5:15 PM EST - 5 months ago

RxSight, Inc. Announces Chief Financial Officer Transition


RxSight price target raised to $10 from $9 at Morgan Stanley

2025-12-02T11:40:27.000Z - 5 months ago

RxSight price target raised to $10 from $9 at Morgan Stanley


RxSight price target raised to $10 from $8 at Stifel

2025-11-06T17:00:27.000Z - 6 months ago

RxSight price target raised to $10 from $8 at Stifel


RxSight price target raised to $9 from $8 at JPMorgan

2025-11-06T12:57:21.000Z - 6 months ago

RxSight price target raised to $9 from $8 at JPMorgan


RxSight Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 6 months ago

RxSight Earnings Call Transcript: Q3 2025


RxSight, Inc. Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 6 months ago

RxSight, Inc. Reports Third Quarter 2025 Financial Results


RxSight Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

RxSight Earnings Call Transcript: Q2 2025


RxSight, Inc. Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 10 months ago

RxSight, Inc. Reports Second Quarter 2025 Financial Results


BryGuy29
BryGuy29 May. 7 at 2:01 PM
$RXST yikes. Great tech, but honestly, this company should be acquired by a bigger company to open the tech to more offices.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 8:10 PM
$RXST Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.38 down -90.00% YoY • Reported revenue of $30.89M down -18.48% YoY • RxSight expects to incur net operating losses and negative cash flows for the foreseeable future, despite anticipating revenue growth from expanded sales and marketing efforts, with current cash sufficient for at least 12 months.
0 · Reply
SuperGreenToday
SuperGreenToday May. 1 at 6:39 PM
0 · Reply
OPmoney
OPmoney Apr. 23 at 6:02 PM
$RXST PSA update after 22 days Post-Op: 4/21 was 1st UV tweek to LALs - looking at seeing 20/15 in both eyes. Still wearing UV blocker dark sunglasses, iVIZIA Sterile Lubricant Eye Drops for Dry Eyes every hour or two, using +2.75 readers for close work and +1.25 for desk/computer screens. So far, so good, clearer and brighter - future so bright ...
1 · Reply
focafoca99
focafoca99 Apr. 8 at 10:21 PM
$RXST highlighted the milestone of 300,000 Light Adjustable Lens implants and a heavy scientific presence at ASCRS 2026.
0 · Reply
OPmoney
OPmoney Apr. 6 at 7:21 PM
$RXST PSA #1 from 2025: As far as posting up insight on another patient's own LAL experience Nov. 2023 in one eye. There is some improvement. Can see because cataract was removed, however doctor's recent reco, after a year of own blood Serum-eyedrops for severe dry eye is now try Oxervate $100K eye drops. As of 10-days ago cornea looks like "sand paper." Same thing was said after lock-in over a year ago. NO FUN, plus this patient also suffers from Trigeminal neuralgia - no pain- only numbness on same side of face as LAL since. While there is visual improvement since the cataract was removed, the road post "lock-in" has been complicated by chronic ocular surface issues: The "Sandpaper" Effect: A recent exam revealed the cornea still looks like "sandpaper." This is the same condition reported after the initial lock-in over a year ago. The battle with corneal health continues. It’s a reminder that even with the best lens technology, the "window" (the cornea) has to be clear for it to work.
1 · Reply
OPmoney
OPmoney Apr. 6 at 7:09 PM
$RXST PSA: After undergoing a vitrectomy in both eyes this past September, then earning early onset cataracts - I just spent 10K and am now the proud owner of RxSight Light Adjustable Lenses (LALs) in each eye. Here is the current status: Distance Vision: Five days post-op and things are looking pretty clear in both. AMAZING how clear and bright everything is. The Rx does not match. There is a glare line in dark, looking at lightbulb from 11 to 5 in left and 10 to 4 in right. Near Vision: Currently using +2.75 readers for typing and close work. Maintenance: On a regimen of eye drops 3x daily. UV Dark Glasses mandatory outdoors, not so much indoors. Next Steps: Follow-up appointment scheduled in 10 days. So far, so good! It’s quite an investment, but the progress is encouraging. Added one new "floater" in left eye and two in the right. 1st lock-in is weeks away. Feel free to DM with any questions or concerns.
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:29 PM
$RXST to appear at the Needham Virtual Healthcare Conference on April 16.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 3:52 PM
$RXST Share Price: $6.33 Contract Selected: Sep 18, 2026 $5 Calls Buy Zone: $2.52 – $3.12 Target Zone: $4.34 – $5.30 Potential Upside: 62% ROI Time to Expiration: 174 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
KOWALSK1
KOWALSK1 Mar. 23 at 10:46 AM
$RXST Rxsight inc. ✅️ BUY ZONE 6.41 to 6.35 ✋️ RISK BELOW 6.18 💲PT. 6.75 6.80 7.20 7.64 8.10 + Follow for more
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 11 at 9:06 PM
$RXST RSI: 33.11, MACD: -0.3978 Vol: 0.51, MA20: 8.06, MA50: 8.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 7:06 PM
$RXST RSI: 34.70, MACD: -0.3582 Vol: 0.45, MA20: 8.31, MA50: 9.55 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DrLukas19
DrLukas19 Feb. 26 at 4:38 PM
$RXST not a good look. Seems the LAL effictivness vs. fixed IOL is not as large as once previously thought. The tech seems promising but the physician adoption and utilization rate is telling a different story.
0 · Reply
healthcareguru
healthcareguru Feb. 26 at 3:15 PM
$RXST Time to Buy…turnaround story in play with adult mgmt in place. That was the last cut, reset to estimates…now it’s a beat/raise story with material multiple expansion potential. Realistic to see $15-20 in a year. 👍 $IHI $XLV $IWM $XBI
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 25 at 9:13 PM
$RXST Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.22 down -46.67% YoY • Reported revenue of $32.61M down -18.92% YoY • RxSight provided full year 2026 guidance, projecting revenue of $120.0 to $135M, gross margin of 70% to 72%, and operating expenses between $150M and $160M, reflecting lower LDD placements.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 10:48 PM
$RXST Current Stock Price: $8.63 Contracts to trade: $7.5 RXST Mar 20 2026 Call Entry: $2.40 Exit: $3.07 ROI: 28% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
topstockalerts
topstockalerts Feb. 17 at 1:08 PM
$RXST there it goes!! 🚨
0 · Reply
char13
char13 Feb. 17 at 12:27 PM
$PLYX 100% $BODI 12% $CMPS 16% $RXST 25% $OBAI 92%
0 · Reply
char13
char13 Feb. 17 at 10:50 AM
$RXST value play
0 · Reply